Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is an uncommon bone marrow disorder associated with hemolytic anemia, thrombosis, and cytopenias. Prior to 2007, treatment for PNH was limited and patients with PNH were treated with corticosteroids, anticoagulation for thrombosis, and iron supplementation for their chronic iron deficiency secondary to intravascular hemolysis(1). In fact a hallmark feature of PNH was iron deficiency and iron supplementation continues to be recommended as a treatment for the manifestations of PNH. With the introduction of C5 complement factor inhibitor treatments, potential long term manifestations of treatment need to be considered including the possibility of iron overload. This article is protected by copyright. All rights reserved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
